Bristol Myers-Squibb completed its acquisition of Zymogenetics on October 12th, 2010, in a deal worth over $735 million. Shareholders will receive $9.75 per share. ZymoGenetics has now become a wholly-owned subsidiary of Bristol-Myers Squibb.
Bristol-Myers Squibb is a global biopharmaceutical company with sales of $18.8 billion in 2009. Zymogenetics develops novel protein drugs and raised $120 million through public offerings in 2002. The company is currently marketing a product called RECOTHROM which aids hemostasis, but also has other protein medications in development including treatments for Hepatitis C and metastatic melanoma.